ÀÎÀ¯µÎÁ¾ ¹ÙÀÌ·¯½º 16(HPV16) ¾ç¼º¾Ï : ½ÃÀå ÀλçÀÌÆ®, ¿ªÇÐ ¹× ½ÃÀå ¿¹Ãø(-2034³â)
Human Papillomavirus 16-positive (HPV16+) Cancers - Market Insight, Epidemiology, and Market Forecast - 2034
»óǰÄÚµå : 1506945
¸®¼­Ä¡»ç : DelveInsight Business Research LLP
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 200 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 7,950 £Ü 11,013,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 11,925 £Ü 16,519,000
PDF (2-3 User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 3¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 15,900 £Ü 22,026,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 23,850 £Ü 33,039,000
PDF (Global License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

ÀÎÀ¯µÎÁ¾ ¹ÙÀÌ·¯½º 16(HPV16) ¾ç¼º¾Ï ½ÃÀåÀº ÇâÈÄ ¸î ³âµ¿¾È ÀÌ Áúȯ¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í Àü ¼¼°è ÀÇ·áºñ ÁöÃâÀÌ Áõ°¡ÇÔ¿¡ µû¶ó º¯È­ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

±â¾÷°ú ¿¬±¸±â°üµéÀº Àΰ£À¯µÎÁ¾¹ÙÀÌ·¯½º 16(HPV16) ¾ç¼º¾ÏÀÇ ¿¬±¸°³¹ß¿¡ ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖ´Â µµÀü°úÁ¦¸¦ Æò°¡ÇÏ°í ±âȸ¸¦ ¸ð»öÇϱâ À§ÇØ ³ë·ÂÇϰí ÀÖ½À´Ï´Ù. °³¹ß ÁßÀÎ Ä¡·á¹ýÀº Áúº´À» Ä¡·á/°³¼±Çϱâ À§ÇÑ »õ·Î¿î Á¢±Ù¹ý¿¡ ÃÊÁ¡À» ¸ÂÃß¾ú½À´Ï´Ù. ÁÖ¿ä ±â¾÷µéÀº Àΰ£À¯µÎÁ¾¹ÙÀÌ·¯½º 16(HPV16) ¾ç¼º¾Ï Ä¡·áÁ¦ °³¹ß¿¡ Âü¿©Çϰí ÀÖ½À´Ï´Ù. »õ·Î¿î Ä¡·á¹ýÀÇ µîÀåÀº Àΰ£À¯µÎÁ¾¹ÙÀÌ·¯½º 16 ¾ç¼º(HPV16) ¾Ï ½ÃÀå¿¡ Å« ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä 7°³±¹¿¡¼­ ÀÎÀ¯µÎÁ¾ ¹ÙÀÌ·¯½º 16(HPV16) ¾ç¼º¾Ï ½ÃÀåÀ» Á¶»çÇßÀ¸¸ç, ½ÃÀå °³¿ä¿Í ÇÔ²² ¿ªÇÐ, ȯÀÚ µ¿Çâ, »õ·Î¿î Ä¡·á¹ý, 2034³â±îÁö ½ÃÀå ±Ô¸ð ¿¹Ãø, ÀÇ·á ¹ÌÃæÁ· ¼ö¿ä µîÀ» Á¦°øÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå Áß¿ä ÀλçÀÌÆ®

Á¦2Àå ÀÎÀ¯µÎÁ¾ ¹ÙÀÌ·¯½º 16(HPV16) ¾ç¼º¾ÏÀÇ °³¿ä

Á¦3Àå ÀÎÀ¯µÎÁ¾ ¹ÙÀÌ·¯½º 16 ¾ç¼º(HPV16) ¾Ï °æÀï Á¤º¸ ºÐ¼®

Á¦4Àå ÀÎÀ¯µÎÁ¾ ¹ÙÀÌ·¯½º 16(HPV16) ¾ç¼º¾Ï: ½ÃÀå °³¿ä

Á¦5Àå ÀÎÀ¯µÎÁ¾ ¹ÙÀÌ·¯½º 16(HPV16) ¾ç¼º¾Ï: ÁúȯÀÇ ¹è°æ°ú °³¿ä

Á¦6Àå ȯÀÚ µ¿Çâ

Á¦7Àå ÀÎÀ¯µÎÁ¾ ¹ÙÀÌ·¯½º 16(HPV16) ¾ç¼º¾ÏÀÇ ¿ªÇаú ȯÀÚ±º

Á¦8Àå Ä¡·á ¾Ë°í¸®Áò, ÇöÀçÀÇ Ä¡·á¹ý ¹× ÀÇ·áÇàÀ§

Á¦9Àå ¹ÌÃæÁ· ¿å±¸

Á¦10Àå Àΰ£À¯µÎÁ¾¹ÙÀÌ·¯½º 16 ¾ç¼º(HPV16) ¾Ï Ä¡·áÀÇ ÁÖ¿ä Æò°¡ Ç׸ñ

Á¦11Àå ½ÃÆÇ Á¦Ç°

Á¦12Àå »õ·Î¿î Ä¡·á¹ý

Á¦13Àå ÀÎÀ¯µÎÁ¾ ¹ÙÀÌ·¯½º 16(HPV16) ¾ç¼º¾Ï : ÁÖ¿ä 7°³±¹ ½ÃÀå ºÐ¼®

Á¦14Àå ¼Ó¼º ºÐ¼®

Á¦15Àå ÁÖ¿ä 7°³±¹ : ½ÃÀå Àü¸Á

Á¦16Àå Àΰ£À¯µÎÁ¾¹ÙÀÌ·¯½º 16 ¾ç¼º(HPV16) ¾Ï¿¡ ´ëÇÑ Á¢±Ù¼º ¹× ±Þ¿© °³¿ä

Á¦17Àå KOLÀÇ °ßÇØ

Á¦18Àå ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ

Á¦19Àå ½ÃÀåÀÇ À庮

Á¦20Àå ºÎ·Ï

Á¦21Àå DelveInsightÀÇ ¼­ºñ½º ³»¿ë

Á¦22Àå ¸éÃ¥»çÇ×

Á¦23Àå DelveInsight¿¡ ´ëÇØ

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

DelveInsight's "Human Papillomavirus 16-positive (HPV16+) Cancers - Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Human Papillomavirus 16-positive (HPV16+) Cancers, historical and forecasted epidemiology as well as the Human Papillomavirus 16-positive (HPV16+) Cancers market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Human Papillomavirus 16-positive (HPV16+) Cancers market report provides current treatment practices, emerging drugs, Human Papillomavirus 16-positive (HPV16+) Cancers market share of the individual therapies, current and forecasted Human Papillomavirus 16-positive (HPV16+) Cancers market size from 2020 to 2034 segmented by seven major markets. The Report also covers current Human Papillomavirus 16-positive (HPV16+) Cancers treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

Study Period: 2020-2034

Human Papillomavirus 16-positive (HPV16+) Cancers Disease Understanding and Treatment Algorithm

The DelveInsight Human Papillomavirus 16-positive (HPV16+) Cancers market report gives a thorough understanding of the Human Papillomavirus 16-positive (HPV16+) Cancers by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Human Papillomavirus 16-positive (HPV16+) Cancers.

Treatment

It covers the details of conventional and current medical therapies available in the Human Papillomavirus 16-positive (HPV16+) Cancers market for the treatment of the condition. It also provides Human Papillomavirus 16-positive (HPV16+) Cancers treatment algorithms and guidelines in the United States, Europe, and Japan.

Human Papillomavirus 16-positive (HPV16+) Cancers Epidemiology

The Human Papillomavirus 16-positive (HPV16+) Cancers epidemiology division provide insights about historical and current Human Papillomavirus 16-positive (HPV16+) Cancers patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Human Papillomavirus 16-positive (HPV16+) Cancers epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2020 to 2034.

Country Wise-Human Papillomavirus 16-positive (HPV16+) Cancers Epidemiology

The epidemiology segment also provides the Human Papillomavirus 16-positive (HPV16+) Cancers epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Human Papillomavirus 16-positive (HPV16+) Cancers Drug Chapters

Drug chapter segment of the Human Papillomavirus 16-positive (HPV16+) Cancers report encloses the detailed analysis of Human Papillomavirus 16-positive (HPV16+) Cancers marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Human Papillomavirus 16-positive (HPV16+) Cancers clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Human Papillomavirus 16-positive (HPV16+) Cancers treatment.

Human Papillomavirus 16-positive (HPV16+) Cancers Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Human Papillomavirus 16-positive (HPV16+) Cancers treatment.

Human Papillomavirus 16-positive (HPV16+) Cancers Market Outlook

The Human Papillomavirus 16-positive (HPV16+) Cancers market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Human Papillomavirus 16-positive (HPV16+) Cancers market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Human Papillomavirus 16-positive (HPV16+) Cancers market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Human Papillomavirus 16-positive (HPV16+) Cancers market in 7MM is expected to change in the study period 2020-2034.

Key Findings

This section includes a glimpse of the Human Papillomavirus 16-positive (HPV16+) Cancers market in 7MM.

The United States Market Outlook

This section provides the total Human Papillomavirus 16-positive (HPV16+) Cancers market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Human Papillomavirus 16-positive (HPV16+) Cancers market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Human Papillomavirus 16-positive (HPV16+) Cancers market size and market size by therapies in Japan is also mentioned.

Human Papillomavirus 16-positive (HPV16+) Cancers Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Human Papillomavirus 16-positive (HPV16+) Cancers market or expected to get launched in the market during the study period 2020-2034. The analysis covers Human Papillomavirus 16-positive (HPV16+) Cancers market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Human Papillomavirus 16-positive (HPV16+) Cancers Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Human Papillomavirus 16-positive (HPV16+) Cancers key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Human Papillomavirus 16-positive (HPV16+) Cancers emerging therapies.

Reimbursement Scenario in Human Papillomavirus 16-positive (HPV16+) Cancers

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Human Papillomavirus 16-positive (HPV16+) Cancers domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Human Papillomavirus 16-positive (HPV16+) Cancers market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Human Papillomavirus 16-positive (HPV16+) Cancers Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

Report Highlights:

Human Papillomavirus 16-positive (HPV16+) Cancers Report Insights

Human Papillomavirus 16-positive (HPV16+) Cancers Report Key Strengths

Human Papillomavirus 16-positive (HPV16+) Cancers Report Assessment

Key Questions:

Market Insights:

Epidemiology Insights:

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

Reasons to buy:

Table of Contents

1. Key Insights

2. Executive Summary of Human Papillomavirus 16-positive (HPV16+) Cancers

3. Competitive Intelligence Analysis for Human Papillomavirus 16-positive (HPV16+) Cancers

4. Human Papillomavirus 16-positive (HPV16+) Cancers: Market Overview at a Glance

5. Human Papillomavirus 16-positive (HPV16+) Cancers: Disease Background and Overview

6. Patient Journey

7. Human Papillomavirus 16-positive (HPV16+) Cancers Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Unmet Needs

10. Key Endpoints of Human Papillomavirus 16-positive (HPV16+) Cancers Treatment

11. Marketed Products

List to be continued in report

12. Emerging Therapies

List to be continued in report

13. Human Papillomavirus 16-positive (HPV16+) Cancers: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Human Papillomavirus 16-positive (HPV16+) Cancers

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

The table of contents is not exhaustive; the final content may vary.

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â